2020台灣生技月 Bio Taiwan 生物科技大展

2020 台灣生技月 南港展覽館

講師

BELX BioPharmaceutical Co. Ltd.

Company Presentations

Wednesday, July 22 Company Presentations 1–Pharma

BELX BioPharmaceutical Co. Ltd.

Company Info

Name /BELX BioPharmaceutical Co. Ltd.

Address /Rm. 536, Bldg. 52, 195 Sec. 4, Chung Hsing Rd., Chutung, Hsinchu, 31057, Taiwan, ROC

Website /www.belxbiopharma.com

Presenter

Name /Ching-Yuan Lee

Title /Chief Business Officer

Email /cyianlee@belxbiopharma.com

Telephone /(Work) +886-3-5910151 x 205

Fax /+886-3-5910181

Mobile /+886-955304440

Company Type

Pharmaceutical

About the Company

BELX BioPharmaceutical, established in Mar., 2016, originated from a botanical new drug development project which started in the year of 2000 at Industrial Technology Research Institute (ITRI) in Taiwan. BELX’s top management integrates original core R&D members from ITRI as well as industrial and academic elites from local and overseas institutes. The company is dedicated in commercializing innovative botanical new drugs to treat patients who suffer from cancers and other chronicle diseases. The lead candidate drug, BEL-X, is in a phase I trial targeting late stage solid tumors patients. The company’s core technologies are well protected by 47 patents worldwide.

Brief Description of main products or services

Derived from one single plant which has been used as both medicine and food in Chinese history for over 1000 years, BEL-X has an excellent safety profile and offers a novel ROS (reactive oxygen species) balance mechanism of action. This unique feature allows extra flexibility in development. First of all, BEL-X is effective in treating multiple types of solid tumors. Secondly, it can be used as a single drug and/or in combination with current treatment drugs to increase efficacy, decrease side effects, or both. Pre-clinical animal models show astonishing results in significantly increasing survival and maintaining normal physical activities. These unique characteristics of BEL-X make it a perfect fit for the unmet medical needs in the cancer patients, who need to extend survival and to have good quality of life.

        The ongoing phase I clinical trial is being executed at both National Taiwan University Hospital and National Cheng Kung University Hospital, and will be completed by Sept., 2020.

        BELX plans to raise $20M in the next 5 years for conducting subsequent clinical trials and studies of BEL-X as well as increasing R&D projects to expand BEL-X’s indications. The company is also seeking local and global licensing and/or co-development partners.

Contact Person

Name /Ching-Yuan Ian Lee

Email /cyianlee@belxbiopharma.com

Phone /+886-955304440